Revenue is highly volatile and milestone-driven, swinging from $61K to $30.6M in a single quarter, while operating margins have remained deeply negative, reaching -156.0% in 2026Q2, indicating a structural inability to cover high fixed R&D costs.
Editas Medicine, Inc. (EDIT) annual income statement — 13-year revenue, gross profit & net income history
| Metric | TTM | Dec'25 | Dec'24 | Dec'23 | Dec'22 | Dec'21 | Dec'20 | Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | Dec'13 |
|---|
| Sales/Revenue | 47.01M | 40.52M | 32.31M | 78.12M | 19.71M | 25.54M | 90.73M | 20.53M | 31.94M | 13.73M | 6.05M | 1.63M | 0 | 0 |
| Revenue Growth % | 20.83% | 25.39% | -58.64% | 296.32% | -22.83% | -71.85% | 341.93% | -35.71% | 132.64% | 126.8% | 271.58% | - | - | - |
| Cost of Goods Sold | 20.26M | 0 | 199.25M | 6.06M | 6.34M | 5.05M | 158M | 96.9M | 90.65M | 83.16M | 56.98M | 18.85M | 5.07M | 1.59M |
| COGS % of Revenue | - | - | 616.6% | 7.76% | 32.15% | 19.78% | 174.13% | 471.96% | 283.85% | 605.76% | 941.33% | 1156.91% | - | - |
| Gross Profit | 26.75M | 40.52M | -166.93M | 72.06M | 13.38M | 20.49M | -67.26M | -76.37M | -58.72M | -69.43M | -50.93M | -17.22M | -5.07M | -1.59M |
| Gross Margin % | 56.9% | 100% | -516.6% | 92.24% | 67.85% | 80.22% | -74.13% | -371.96% | -183.85% | -505.76% | -841.33% | -1056.91% | - | - |
| Gross Profit Growth % | - | 124.27% | -331.66% | 438.76% | -34.73% | 130.46% | 11.92% | -30.06% | 15.43% | -36.34% | -195.79% | -239.38% | -219.06% | - |
| Operating Expenses | 108.87M | 139.86M | 84.22M | 241.24M | 239.32M | 213.64M | 67.58M | 64.56M | 145.66M | 133.66M | 103.24M | 36.94M | 12.72M | 3.68M |
| OpEx % of Revenue | - | 345.15% | 260.63% | 308.8% | 1214.11% | 836.35% | 74.48% | 314.43% | 456.1% | 973.64% | 1705.62% | 2267.71% | - | - |
| Selling, General & Admin | 45.51M | 49.9M | 71.99M | 69.65M | 70.7M | 76.18M | 67.58M | 64.56M | 55.01M | 50.5M | 46.26M | 18.09M | 7.65M | 3.63M |
| SG&A % of Revenue | - | 123.16% | 222.77% | 89.16% | 358.69% | 298.24% | 74.48% | 314.43% | 172.25% | 367.88% | 764.28% | 1110.8% | - | - |
| Research & Development | 70.19M | 89.95M | 199.25M | 177.65M | 174.96M | 142.51M | 158M | 96.9M | 90.65M | 83.16M | 56.98M | 18.85M | 5.07M | 1.59M |
| R&D % of Revenue | - | 222% | 616.6% | 227.4% | 887.57% | 557.89% | 174.13% | 471.96% | 283.85% | 605.76% | 941.33% | 1156.91% | - | - |
| Other Operating Expenses | -1000K | 0 | -187.01M | -6.06M | -6.34M | -5.05M | -158M | -96.9M | 328K | 587K | -57K | -37.45M | -928K | 0 |
| Operating Income | -82.12M | -99.34M | -251.15M | -169.18M | -225.95M | -193.15M | -134.84M | -140.92M | -113.73M | -119.93M | -97.19M | -35.31M | -12.72M | -5.22M |
| Operating Margin % | -174.71% | -245.15% | -777.22% | -216.56% | -1146.26% | -756.13% | -148.61% | -686.39% | -356.1% | -873.64% | -1605.62% | -2167.71% | - | - |
| Operating Income Growth % | - | 60.45% | -48.45% | 25.12% | -16.98% | -43.24% | 4.32% | -23.91% | 5.17% | -23.4% | -175.23% | -177.54% | -143.74% | - |
| EBITDA | -79.7M | -94.06M | -245.34M | -163.12M | -219.61M | -188.09M | -130.88M | -138.09M | -110.47M | -117.25M | -95.99M | -34.84M | -12.57M | -5.22M |
| EBITDA Margin % | -169.55% | -232.13% | -759.25% | -208.8% | -1114.11% | -736.35% | -144.25% | -672.6% | -345.91% | -854.09% | -1585.76% | -2138.8% | - | - |
| EBITDA Growth % | 65.83% | 61.66% | -50.41% | 25.73% | -16.76% | -43.71% | 5.22% | -25% | 5.78% | -22.15% | -175.5% | -177.26% | -140.87% | - |
| D&A (Non-Cash Add-back) | 2.42M | 5.28M | 5.81M | 6.06M | 6.34M | 5.05M | 3.96M | 2.83M | 3.25M | 2.68M | 1.2M | 471K | 157K | 3K |
| EBIT | -72.65M | -153.89M | -238.92M | -153.22M | -220.43M | -192.5M | -134.84M | -140.92M | -113.73M | -119.35M | -97.25M | -72.76M | -12.72M | -5.22M |
| Net Interest Income | -1.49M | 2.14M | 14.06M | 17.57M | 5.52M | 607K | 2.6M | 7.31M | 3.44M | -978K | 62K | -143K | 0 | 0 |
| Interest Income | -3.6M | 8.31M | 14.06M | 17.57M | 5.52M | 607K | 2.6M | 7.31M | 3.44M | 0 | 62K | 0 | 0 | 0 |
| Interest Expense | -2.1M | 6.17M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 978K | 0 | 143K | 34K | 0 |
| Other Income/Expense | 8.17M | -60.72M | 14.06M | 15.96M | 5.52M | 644K | 18.86M | 7.18M | 3.77M | -391K | 5K | -37.59M | -962K | -54K |
| Pretax Income | -73.95M | -160.06M | -237.09M | -153.22M | -220.43M | -192.5M | -115.98M | -133.75M | -109.95M | -120.32M | -97.18M | -72.9M | -13.69M | -5.27M |
| Pretax Margin % | -157.32% | -395.01% | -733.72% | -196.13% | -1118.26% | -753.61% | -127.82% | -651.43% | -344.28% | -876.49% | -1605.53% | -4475.14% | - | - |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -1.12M | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0.93% | 0% | 0% | 0% | 0% |
| Net Income | -73.95M | -160.06M | -237.09M | -153.22M | -220.43M | -192.5M | -115.98M | -133.75M | -109.95M | -120.32M | -97.18M | -72.9M | -13.69M | -5.35M |
| Net Margin % | -157.32% | -395.01% | -733.72% | -196.13% | -1118.26% | -753.61% | -127.82% | -651.43% | -344.28% | -876.49% | -1605.53% | -4475.14% | - | - |
| Net Income Growth % | 68.78% | 32.49% | -54.74% | 30.49% | -14.51% | -65.98% | 13.29% | -21.64% | 8.62% | -23.81% | -33.31% | -432.7% | -155.84% | - |
| Net Income (Continuing) | -73.95M | -160.06M | -237.09M | -153.22M | -220.43M | -192.5M | -115.98M | -133.75M | -109.95M | -120.32M | -97.18M | -72.9M | -13.69M | -5.27M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.62 | -1.80 | -2.88 | -2.02 | -3.21 | -2.85 | -1.98 | -2.47 | -2.33 | -2.98 | -3.02 | -2.04 | -5.34 | -0.18 |
| EPS Growth % | 73.76% | 37.5% | -42.57% | 37.07% | -12.63% | -43.94% | 19.84% | -6.01% | 21.81% | 1.32% | -48.04% | 61.8% | -2866.67% | - |
| EPS (Basic) | - | -1.80 | -2.88 | -2.02 | -3.21 | -2.85 | -1.98 | -2.47 | -2.33 | -2.98 | -3.02 | -2.04 | -5.34 | -0.18 |
| Diluted Shares Outstanding | 119.29M | 88.75M | 82.34M | 75.97M | 68.66M | 67.62M | 58.61M | 49.98M | 47.1M | 40.32M | 32.22M | 35.7M | 2.56M | 30.05M |
| Basic Shares Outstanding | 119.29M | 88.75M | 82.34M | 75.97M | 68.66M | 67.62M | 58.61M | 49.98M | 47.1M | 40.32M | 32.22M | 35.7M | 2.56M | 30.05M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quick answers to the most common questions about buying EDIT stock.
For fiscal year 2025, Editas Medicine, Inc. (EDIT) reported total revenue of $40.5M.
Editas Medicine, Inc. (EDIT) reported a net loss of $160.1M for the fiscal year ending 2025.
Editas Medicine, Inc. (EDIT) reported an operating income of $-99.3M, resulting in an operating profit margin of -245.2%. This margin reflects the operational efficiency of the business before interest and taxes.
Editas Medicine, Inc. (EDIT) generated $40.5M in gross profit for the year, representing a gross profit margin of 100.0%. This demonstrates the company's core pricing power and production efficiency.
Key Metrics
Top Statement Risk
Persistent cash burn and negative margins
Metrics are mathematically derived from official filings.
Volatile Revenue Driven by Lumpy Milestones
Editas's revenue trajectory is highly erratic, swinging from $61K in 2024Q3 to $30.6M in 2024Q4, then to $24.7M in 2025Q4, indicating a business model reliant on non-recurring, milestone-based payments rather than sustainable commercial sales.
The extreme quarterly volatility, with revenue growth rates ranging from -98.9% to +122.7%, suggests the company lacks a predictable, recurring revenue stream. This pattern is characteristic of early-stage biotechs dependent on partnership milestones or licensing fees, making forward revenue forecasting exceptionally difficult and highlighting a lack of commercial traction.
Structural Margin Negativity and Volatility
Gross margins have been deeply negative for most of the period, with a reported -162.2% in 2025Q3, indicating that the cost of revenue consistently exceeds the revenue generated, a fundamental challenge for achieving profitability.
The erratic gross margin, which swung to 100% in quarters with zero COGS (2025Q4, 2026Q2), appears to be an accounting artifact rather than a sign of operational improvement. The underlying trend shows a company where the direct costs of its programs, likely clinical trial and manufacturing expenses, are not being covered by its current revenue base.
High Fixed R&D Burden Amidst Revenue Lulls
Research and development expenses have remained consistently high, averaging over $30M per quarter, while revenue has often been minimal, creating a massive structural operating loss that dwarfs any gross profit.
The sustained high R&D spend, even in quarters with negligible revenue (e.g., $47.6M R&D vs. $61K revenue in 2024Q3), indicates a commitment to advancing a pipeline without near-term commercial offset. This cost structure necessitates continuous external financing and underscores the long-term, high-risk nature of the business.
Negative Operating Leverage Amplifies Losses
Operating losses have consistently exceeded gross profit, with operating margins reaching -156.0% in 2026Q2, demonstrating that the company's overhead structure is not scaling down with revenue volatility, thereby magnifying losses.
The persistent gap between gross profit and operating income, driven by substantial SG&A and R&D, shows a lack of operating leverage. In quarters with low revenue, the fixed cost base results in catastrophic operating margins, indicating that the path to profitability requires not just revenue growth, but a fundamental restructuring of the cost base.
Sustainability of Cash Burn and Financing Risk
The company's net losses have averaged over $40M per quarter over the last ten periods, a rate of cash consumption that raises serious questions about its ability to fund operations without dilutive financing or a near-term partnership infusion.
The most significant challenge to the income statement narrative is the sheer magnitude and persistence of the losses relative to any revenue generation. With net margins consistently negative and often exceeding -100%, the financial model appears unsustainable without a material change in business trajectory, such as a major partnership deal or regulatory approval, which remains uncertain.